• Trump's executive order implements a "Most Favored Nation" policy for Medicare drug pricing.
  • The policy targets medications administered in doctors' offices, with potential savings of 30-80%.
  • Pharmaceutical industry response remains uncertain as the order revives a previously stalled initiative.

A Bold Move on Drug Pricing

President Trump announced Sunday evening via Truth Social that he will sign an executive order Monday morning implementing a "Most Favored Nation" policy for Medicare prescription drug purchases. The controversial measure would require Medicare to pay no more than the lowest price paid by other developed nations for certain medications - primarily those administered in clinical settings like cancer infusions and injectable drugs.

"Prices will come down from 59 to 80 to 90%," Trump claimed in his post, though subsequent administration statements suggest more modest projections of 30-80% reductions. The signing ceremony is scheduled for 9:00 AM at the White House on May 12.

Industry Implications

The move represents Trump's second attempt at this pricing reform after failing to implement it during his first term. Health and Human Services Secretary Robert F. Kennedy Jr. has been vocal about the pricing disparities, recently citing examples like Ozempic costing significantly more in the U.S. than in Europe.

Medicare, which covers approximately 70 million Americans, could see substantial savings - though experts caution Trump's "trillions" claim may be exaggerated. The policy specifically targets Part B drugs, which account for about 8% of Medicare's prescription spending but include some of the most expensive specialty medications.

Uncharted Territory

Pharmaceutical companies have historically resisted such measures, and legal challenges are expected. The order's implementation timeline remains unclear, particularly how quickly price changes might reach patients. When reached for comment, a spokesperson for PhRMA declined to provide an immediate statement but confirmed the trade group was reviewing the order's details.

Administration officials suggest the policy could serve as a model for broader drug pricing reforms, though congressional action would be required to expand it beyond Medicare. Democrats have long advocated for similar measures but have opposed Trump's unilateral approach through executive action.

Correction: An earlier version of this article overstated potential price reductions based on preliminary statements. Projected savings are currently estimated at 30-80%, not the broader range initially suggested.